Mylan’s Other EpiPen Classification Issue and Unresolved Overhang
(This is an excerpt from an article I originally published on Seeking Alpha on October 19, 2016. Click here to read the entire piece.) Mylan (MYL) is down 13% (and as much as 17%) since I argued the company was “out of tune” with an angry chorus that promised to place a lot of short-term … Read more